Status:
UNKNOWN
Effects of Pioglitazone Treatment on Sympathetic Nervous System Function in Metabolic Syndrome Obesity
Lead Sponsor:
Baker Heart Research Institute
Collaborating Sponsors:
National Heart Foundation, Australia
Conditions:
Metabolic Syndrome
Eligibility:
All Genders
45-65 years
Phase:
PHASE3
Brief Summary
An abdominal distribution of fat is associated with the greatest heart disease risk, because commonly, several risk factors of metabolic origin cluster in these individuals. When this occurs the condi...
Detailed Description
The rapidly growing burden of obesity together with a population that is becoming older raises the importance of effective strategies for the primary prevention and treatment of the metabolic syndrome...
Eligibility Criteria
Inclusion
- Males and females aged 45-65 years,
- non-smokers,
- HOMA index \> 2.5 and
- who meet ATP III criteria for the metabolic syndrome
Exclusion
- History of diabetes,
- previous MI, stroke, heart failure, impaired hepatic or renal function.
- Inability to cease medications which may affect study parameters.
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2013
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT00408850
Start Date
November 1 2008
End Date
February 1 2013
Last Update
January 17 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baker Heart Research Institute
Melbourne, Victoria, Australia, 8008